Table 2. Comparison of clinical outcomes based on EGFR mutation status.
| EFGR Positive = 142 | EGFR negative = 140 | P-value | |
|---|---|---|---|
| Overall Recurrence (All stage), N (%) | 32 | 29 | |
| Stage 1, N (%) | 18 | 12 | |
| Stage 2, N (%) | 2 | 7 | |
| Stage 3, N (%) | 12 | 10 | |
| Metastatic Recurrence among those who recurred, N (%) | 31 (97%) | 21 (68%) | 0.007 |
| Stage 1, N (%) | 17 (94%) | 6 (50%) | 0.02 |
| Stage 2, N (%) | 2 (100%) | 6 (86%) | > 0.99 |
| Stage 3, N (%) | 12 (100%) | 9 (75%) | 0.22 |
| Number of sites of metastasis for those with metastatic recurrence, N (%) | 1: 21 (68%) | 1: 11 (52%) | 0.09 |
| 2: 4 (13%) | 2: 8 (38%) | ||
| 3+: 6 (19%) | 3+: 2 (10%) | ||
| 1 | 21 (68%) | 11 (52%) | |
| 2 | 4 (13%) | 8 (38%) | |
| 3+ | 6 (19%) | 2 (10%) | |
| Progression free survival rates, based on Kaplan-Meier method (95% CI) for All Stages: | > 0.99 | ||
| 1 year (52 weeks) | 0.94 (0.89, 0.98) | 0.91 (0.86, 0.96) | |
| 2 year (104 weeks) | 0.83 (0.76, 0.91) | 0.81 (0.74, 0.89) | |
| 5 year (260 weeks) | 0.59 (0.47, 0.73) | 0.60 (0.50, 0.73) | |
| Median Progression Free Survival (IQR) in weeks (All stages)* | N/A (193, N/A) | N/A (260, N/A) | |
| Stage 1 | N/A (N/A, N/A) | N/A (N/A, N/A) | |
| Stage 2 | N/A (186, N/A) | 144 (52, N/A) | |
| Stage 3 | 137 (81, N/A) | 167 (85, N/A) |
*Due to insufficient number of events, point estimates and/or confidence interval bounds were not defined for all cases; these cases are marked as “N/A.”